Search Result

Results for "

dimerizer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (5) Autophagy (4) Bacterial (2) c-Fms (1) c-Myc (4) Calcium Channel (1) EGFR (2) ERK (2) Estrogen Receptor/ERR (2) FKBP (3) Fluorescent Dye (2) Fungal (2) G-quadruplex (1) HIV (3) HIV Protease (1) HuR (1) MyD88 (1) NO Synthase (1) PD-1/PD-L1 (6) Phosphatase (1) Potassium Channel (2) PROTAC Linkers (1) PROTACs (2) SARS-CoV (1) STAT (4) Survivin (2) Trk Receptor (1) Virus Protease (1)
By Research Areas:	Cancer (29) Cardiovascular Disease (2) Endocrinology (2) Infection (7) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (4)

By Targets:

Akt (1)

Apoptosis (5)

Autophagy (4)

Bacterial (2)

c-Fms (1)

c-Myc (4)

Calcium Channel (1)

EGFR (2)

ERK (2)

Estrogen Receptor/ERR (2)

FKBP (3)

Fluorescent Dye (2)

Fungal (2)

G-quadruplex (1)

HIV (3)

HIV Protease (1)

HuR (1)

MyD88 (1)

NO Synthase (1)

PD-1/PD-L1 (6)

Phosphatase (1)

Potassium Channel (2)

PROTAC Linkers (1)

PROTACs (2)

SARS-CoV (1)

STAT (4)

Survivin (2)

Trk Receptor (1)

Virus Protease (1)

By Research Areas:

Cancer (29)

Cardiovascular Disease (2)

Endocrinology (2)

Infection (7)

Inflammation/Immunology (8)

Metabolic Disease (1)

Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131015

HaXS8	Others	Others
HaXS8 is a dimerizer that can promote a covalent and irreversible intracellular dimerization of HaloTag and SNAP-tagged proteins of interest. HaXS8 does not interfere with PI3K/mTOR signaling .

HY-136538

LQZ-7I	Survivin	Cancer
LQZ-7I is a survivin-targeting inhibitor. LQZ-7I inhibits survivin dimerization. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors .

HY-103692

STX-0119

STAT Cancer

STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC₅₀ of 74 μM .
HY-120402

BMS-200

PD-1/PD-L1 Inflammation/Immunology

BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 80 nM. BMS-200 can induce dimerization of PD-L1 .

STX-0119	STAT	Cancer
STX-0119 is a selective, orally active STAT3 dimerization inhibitor. STX-0119 inhibits STAT3 transcription with an IC₅₀ of 74 μM .

BMS-200	PD-1/PD-L1	Inflammation/Immunology
BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 80 nM. BMS-200 can induce dimerization of PD-L1 .

HY-P10114

STAT3-IN-24, cell-permeable PpYLKTK-mts; STAT3 PI	STAT	Cancer
STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a STAT3 peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .

HY-153890

NVOC cage-TMP-Halo	Others	Others
NVOC cage-TMP-Halo is a cell-permeable and photoactivatable protein dimerization inducer. NVOC cage-TMP-Halo can rapidly and reversibly control protein localization in living cells. NVOC cage-TMP-Halo can be used for dynamic cellular processes research .

HY-144121

Ph-Ph+	Bacterial Fungal Apoptosis	Infection Cancer
Ph-Ph+ is a hemiprotonic compound, which is produced from phenanthroline (ph) dimerization. Ph-Ph+ has antitumor, antibacterial and antifungal activities .

HY-12124

BBS-4	NO Synthase	Cardiovascular Disease
BBS-4 is a potent and selective inducible nitric oxide synthase (NOS2) dimerization inhibitor, with an IC₅₀ of 0.49 nM. BBS-4 can protect mice from the cardiovascular dysfunction of sepsis .

HY-18061

Ochromycinone 1 Publications Verification (Rac)-STA-21	STAT Bacterial	Infection Cancer
Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity .

HY-100669

Mycro 3 5 Publications Verification	c-Myc Autophagy	Cancer
Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc . Mycro 3 could be used for the research of pancreatic cancer .

HY-111009

Swinholide A	Fungal	Infection
Swinholide A is the actin-binding marine polyketide and dimerizes actin with the K_d of ~ 50 nM . Swinholide A is a microfilament disrupting marine toxin that stabilizes actin dimers and severs actin filaments. Swinholide A disrupts the actin cytoskeleton of cells.Antifungal activity .

HY-102011

BMS-1166 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-122678

LQZ-7F	Survivin Apoptosis	Cancer
LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC₅₀s of 2.99 and 2.47 µM, respectively .

HY-126558

GA3-AM

Others Others

GA3-AM is a cell permeable analog of the plant hormone gibberellic acid that acts as a chemical dimerizer or chemical inducer of dimerization .

GA3-AM	Others	Others
GA3-AM is a cell permeable analog of the plant hormone gibberellic acid that acts as a chemical dimerizer or chemical inducer of dimerization .

HY-16046

Rimiducid 30+ Cited Publications AP1903	FKBP Apoptosis	Cancer
Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the FKBP domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.

HY-N11101

Procyanidin A5'

Others Others

Procyanidin A5' is A dimerized proanthocyanidin type A .

Procyanidin A5'	Others	Others
Procyanidin A5' is A dimerized proanthocyanidin type A .

HY-18932

DEL-22379 1 Publications Verification	ERK Apoptosis	Cancer
DEL-22379 is an ERK dimerization Inhibitor. DEL-22379 readily binds to ERK2 with a K_d estimated in the low micromolar range, though binding is detectable even at low nanomolar concentrations. ERK2 dimerization is progressively inhibited with an IC₅₀ of ~0.5 μM.

HY-P3833

Yp537

Anti-estrogen
Estrogen Receptor/ERR Endocrinology

Yp537 is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor .

Yp537 Anti-estrogen	Estrogen Receptor/ERR	Endocrinology
Yp537 is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor .

HY-124500

AC-4-130 3 Publications Verification	STAT Apoptosis	Cancer
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML) .

HY-100996

10074-G5

2 Publications Verification

c-Myc Autophagy Cancer

10074-G5 is an inhibitor of c-Myc-Max dimerization with an IC₅₀ of 146 μM.
HY-P3833A

Yp537 TFA

Anti-estrogen TFA
Estrogen Receptor/ERR Endocrinology

Yp537 TFA is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor .

10074-G5 2 Publications Verification	c-Myc Autophagy	Cancer
10074-G5 is an inhibitor of c-Myc-Max dimerization with an IC₅₀ of 146 μM.

Yp537 TFA Anti-estrogen TFA	Estrogen Receptor/ERR	Endocrinology
Yp537 TFA is an estrogen receptor (ER) inhibitor that blocks dimerization of the human estrogen receptor .

HY-150252A

ATIC-IN-1 acetate	Others	Cancer
ATIC-IN-1 (compound 14) acetate is an inhibitor targeting to Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) dimerization with a K_i value of 685 nM. ATIC dimerization is crucial for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity. ATIC-IN-1 acetate exhibits anti-tumor activity via reduction in cell numbers and cell division rates .

HY-114771

α-Truxillic acid

Others Inflammation/Immunology

α-Truxillic acid is form by the dimerization of two molecules of α-trans-cinnamic acid, with anti-inflammatory activities .

α-Truxillic acid	Others	Inflammation/Immunology
α-Truxillic acid is form by the dimerization of two molecules of α-trans-cinnamic acid, with anti-inflammatory activities .

HY-150252

ATIC-IN-1	Others	Cancer
ATIC-IN-1(compound 14) is an inhibitor targeting to Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) dimerization with a K_i value of 685 nM. ATIC dimerization is crucial for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity. ATIC-IN-1 exhibits anti-tumor activity via reduction in cell numbers and cell division rates .

HY-P9912A

Pertuzumab (PBS)

EGFR Cancer

Pertuzumab (PBS), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

Pertuzumab (PBS)	EGFR	Cancer
Pertuzumab (PBS), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-127041

Virstatin	Others	Infection
Virstatin inhibits the pili system synthesis and prevents A. baumannii biofilm formation. Virstatin also inhibits dimerization of the transcriptional activator ToxT .

HY-12702

10058-F4

30+ Cited Publications

c-Myc Autophagy Cancer

10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.

10058-F4 30+ Cited Publications	c-Myc Autophagy	Cancer
10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.

HY-P9912

Pertuzumab 3 Publications Verification	EGFR	Cancer
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-160783

SRI-43265	HuR	Cancer
SRI-43265 (compound 40) is an inhibitor of human antigen R protein (HuR) dimerization, and HuR multimers have been implicated in cancer and inflammatory pathogenesis .

HY-13992

AP20187 20+ Cited Publications B/B Homodimerizer	FKBP	Metabolic Disease
AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.

HY-N8307

Syringaresinol	Others	Cardiovascular Disease Inflammation/Immunology
Syringaresinol is a lignan that can be extracted from from Dragon’s Blood of Dracaena cambodiana. Syringaresinol has anti-inflammatory activity. Syringaresinol also causes vasorelaxation. Syringaresinol elevates NO production through the phosphorylation and dimerization of endothelial NO synthase .

HY-50937

ST 2825 Maximum Cited Publications 64 Publications Verification	MyD88	Inflammation/Immunology
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity .

HY-126316

Zapalog 1 Publications Verification	FKBP	Others
Zapalog is a photocleavable small-molecule heterodimerizer that can be used to repeatedly initiate, and instantaneously terminate, a physical interaction between two target proteins. Zapalog dimerizes any two proteins tagged with the FKBP and DHFR domains until exposure to light causes its photolysis .

HY-122702

PEG6-(CH2CO2H)2	PROTAC Linkers	Others
PEG6-(CH2CO2H)2 is a symmetric PEG PROTAC linker, for the synthesis of Homo-PROTACs which is bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation .

HY-139186

PROTAC KRAS G12C degrader-1	PROTACs	Cancer
PROTAC KRAS G12C degrader-1 is a Cereblon-based KRAS ^G12C PROTAC degrader. PROTAC KRAS G12C degrader-1 induces CRBN/ KRAS ^G12C dimerization and degrades GFP- KRAS ^G12C in reporter cells .

HY-145560

Claficapavir A1752	HIV	Infection
Claficapavir (A1752) is a specific nucleocapsid protein (NC) inhibitor with an IC₅₀ around 1 μM. Claficapavir strongly binds the HIV-1 NC (K_d=20 nM) thereby inhibiting the chaperone properties of NC and leading to good antiviral activity against the HIV-1 .

HY-15148

Tipranavir 5+ Cited Publications PNU-140690	HIV Protease HIV SARS-CoV	Infection
Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC₅₀s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL ^pro activity .

HY-W154295

Purple-β-D-Gal	Fluorescent Dye	Others
Purple-β-D-Gal is a chromogenic β-galactosidase substrate. Intracellular enzymatic hydrolysis of Purple-β-D-Gal generates free indoxyl molecules, which undergo in situ oxidation and subsequent dimerization to produce chromogenic, water-insoluble, indigo precipitates. Purple-β-D-Gal can be used for the detection of β-galactosidase activity .

HY-150259

MDEG-541	PROTACs c-Myc	Cancer
MDEG-541 is a potent MYC-MAX degrader. MDEG-541 is a PROTAC that based on the MYC-MAX dimerization inhibitor 10058-F4 derivative 28RH and Thalidomide (HY-14658). MDEG-541 shows antiproliferative activity. MDEG-541 decreases the expression of GSPT1, MYC, GSPT2, PLK1 protein .

HY-P99245

Emactuzumab RG 7155; RO 5509554	c-Fms	Cancer
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with K_i value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .

HY-146812

DIZ-3	G-quadruplex	Cancer
DIZ-3 is a selective multimeric G4 ligand based on a G4-ligand-dimerizing strategy. DIZ-3 intercalates into the G4-G4 interface, stabilizing the higher-order structure. DIZ-3 induces cell cycle arrest and apoptosis, and thus inhibits cell proliferation in alternative lengthening of telomere (ALT) cancer cells .

HY-134884

INCB086550 PD-1/PD-L1-IN-8	PD-1/PD-L1	Cancer
INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC_50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research .

HY-102011A

BMS-1166 hydrochloride	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-144258

PD-1/PD-L1-IN-14	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of PD-1/PD-L1 interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 .

HY-13750

Ebselen 10+ Cited Publications SPI-1005; PZ-51; CCG-39161	Calcium Channel Virus Protease HIV Phosphatase	Infection Neurological Disease Inflammation/Immunology Cancer
Ebselen (SPI-1005), a glutathione peroxidase mimetic, is a potent voltage-dependent calcium channel (VDCC) blocker . Ebselen potently inhibits M ^pro (IC₅₀=0.67 μM) and COVID-19 virus (EC₅₀=4.67 μM) .Ebselen is an inhibitor of HIV-1 capsid CTD dimerization. Ebselen, an organoselenium compound, can permeate the blood-brain barrier and has anti-inflammatory, antioxidant and anticancer activity .

HY-122214

AC-73 3 Publications Verification	Autophagy	Cancer
AC-73 is a first specific, orally active inhibitor of cluster of differentiation 147 (CD147), which specifically disrupts CD147 dimerization, thereby mainly suppressing the CD147/ERK1/2/STAT3/MMP-2 pathways. AC-73 inhibits the motility and invasion of hepatocellular carcinoma cells . AC-73 is also an anti-proliferative agent and an inducer of autophagy in leukemic cells .

HY-121833

Gambogic amide	Trk Receptor Akt ERK	Neurological Disease Cancer
Gambogic amide is a potent and selective agonist of TrkA and also induces its tyrosine phosphorylation and activation of downstream signaling, including Akt and MAPK. Gambogic amide specifically interacts with the cytoplasmic juxtamembrane domain of the TrkA receptor and triggers its dimerization, leading to activation. Gambogic amide has neuroprotective activity preventing glutamate-induced neuronal cell death. Gambogic amide has improved efficacy in a transient middle cerebral artery occlusion model of stroke and could be used to study neurodegenerative diseases and stroke .

HY-136277

DFHO	Fluorescent Dye	Others
DFHO is a fluorogenic ligand of Corn fluorogenic aptamer. The RNA aptamer, Corn binds DFHO with a K_d value of 70 nM and converts it to a fluorescent form, enabling RNA imaging in cells .

HY-149536

TWIK-1/TREK-1-IN-1	Potassium Channel	Neurological Disease
TWIK-1/TREK-1-IN-1 (compound 2a) is an inhibitor of the TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC₅₀s of 9.36 μM and 14.6 μM, respectively, and has antidepressant-like effects .

HY-152240

PD-1/PD-L1-IN-29	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 (S4-1) is a potent PD-1/PD-L1 inhibitor with an IC₅₀ value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks